Thomas Li, Sr Director at Roche to Speak at 3rd Oncology Biomarkers Conference on Jan 27-28, 2011 CA

Monrovia, CA, November 26, 2010 --(PR.com)-- Thomas Li, Senior Director of Technology Management and US Chief Technology Officer at Hoffmann - La Roche to give a presentation on “Oncology Biomarker Discovery Technologies of Today and Tomorrow” at GTCbio’s 3rd Oncology Biomarkers Conference on January 27-28, 2011 in San Diego, CA.

Dr. Li will review the past and present biomarker discovery technologies. Technology examples will be drawn from genomics, proteomics, glycomics, metabolomics and cellular analysis. Topics will include microarray, amplification, melting curve analysis, immunoassay, autoantibodies, antibody technology, multiplexing, mass spectrometry, immunohistochemistry, in situ hybridization, comparative genomic hybridization, copy number variation, sequencing, flow cytometry, digital imaging, bioinformatics and pathway analysis. Advances in automation, workflow and sample prep will also be covered. Finally future direction of biomarker discovery technologies will also be projected.

Attendees will gain understanding on:
The past and present biomarker technologies
Current limitation of biomarker technologies
Examples of biomarker discovery success story
Future direction of biomarker technology development
History of Biomarker Discovery Technologies
Overview of the current state-of-the-art Biomarker discovery Technologies
Unmet need of biomarker discovery technologies will also be discussed

Dr. Li rose through the scientific and managerial ranks of Rx and DX companies such as Miles Laboratories (Bayer), Syntex (Roche), Hycor (Strategene/Agilent), and the Diagnostic Products Corporation (Siemens), before joining Invitrogen (ABI) and then Roche.

Dr. Li is a member of ASCO and AACR, a Fellow of the American Academy of Allergy, Asthma and Immunology, a Fellow of the Association of Clinical Scientists, a Fellow of the National Academy of Clinical Biochemistry and a Diplomat of the European Academy of Allergology and Clinical Immunology. Dr. Li is also an Associate Member of the Early Detection Research Network at The National Cancer Institute (USA). He is an Adjunct Professor at the Hong Kong Polytechnic University. He has launched over 52 510K and PMA IVD products and 6 Instruments.

###